Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly’s phase 3 double-blind study (MONARCH 2) designed to evaluate the efficacy and safety of abemaciclib, in combination with fulvestrant, in patients with advanced (locoregionally recurrent or metastatic) breast cancer has met its primary endpoint.
Diplomat Pharmacy will distribute Novartis’s newly approved breast cancer drug Kisqali (ribociclib) as a first-line treatment for postmenopausal women with a serious form of the disease.
The US Food and Drug Administration (FDA) has approved Novartis’s Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies, has approved a new indication for Ipsen’s Decapeptyl as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.
AstraZeneca has announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations.
Pfizer is moving forward with Ibrance breast cancer drug as the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA).
Oasmia Pharmaceutical, a developer of a new generation of drugs within human and veterinary oncology, today presented positive results from…
Novartis has announced additional analyses from the Phase III MONALEESA-2 study that show LEE011 (ribociclib) plus letrozole significantly prolonged progression-free…
Novartis gets FDA Priority Review for first-line treatment of HR+/HER2-advanced breast cancer
October is Breast Cancer Awareness Month, a worldwide annual campaign involving thousands of organizations, to highlight the importance of breast awareness, education and research.